Ginsan improved Th1 immune response inhibited by gamma radiation
- 1 March 2005
- journal article
- drug development
- Published by Springer Nature in Archives of Pharmacal Research
- Vol. 28 (3) , 343-350
- https://doi.org/10.1007/bf02977803
Abstract
Gamma radiation causes suppression of the immune function, and immune properties are related to cytokine production. In the present study, the polysaccharide, Ginsan, purified from an ethanol-insoluble fraction of Ginseng (Panax ginseng C.A. Meyer, Araliaceae) water extract was studied to assess its effects on the immunosuppressive activities of gamma radiation. Ginsan was found to stimulate murine normal splenocytes by inducing the mRNA expressions of Th1 and Th2 type cytokines, and also restore the mRNA expression of IFN-γ, Th1 cytokine, after its inhibition by whole-body gamma irradiation. Therefore, Ginsan was found to restore the T lymphocytes function that had been suppressed by gamma irradiation in allogenic MLR (mixed lymphocyte reactions). However, Ginsan exhibited no excessive stimulatory effects on the control group. The above results indicated that Ginsan may constitute a new noble agent for the improvement of gamma radiation-induced immunosuppression.Keywords
This publication has 17 references indexed in Scilit:
- Gamma Irradiation-reduced IFN-γ Expression, STAT1 Signals, and Cell-mediated ImmunityBMB Reports, 2002
- Restoration of Cytotoxic T Lymphocyte Function in Malignant Pleural Effusion: Interleukin-15 vs. Interleukin-2Journal of Interferon & Cytokine Research, 2000
- Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cellsNature, 1996
- Inhibition of Autochthonous Tumor by Ethanol Insoluble Fraction fromPanax ginsengas an ImmunomodulatorPlanta Medica, 1993
- Natural Products as Antitumor Agents: Direct Versus Indirect Mechanisms of Activity of Flavonoids1JNCI Journal of the National Cancer Institute, 1988
- A new immunomodulating compound (AS-101) with potential therapeutic applicationNature, 1987
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985
- T-cell mediated vascular dilatation and hemorrhage induced by antitumour polysaccharidesInternational Journal of Immunopharmacology, 1984
- Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.The Journal of Experimental Medicine, 1982
- In vitro augmentation of natural killing activity by OK-432International Journal of Immunopharmacology, 1981